Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Anebulo Pharmaceuticals, Inc. (ANEB) had Normalized Pre-Tax Income of $-8.48M for the most recently reported fiscal year, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-8.48M |
|
-- |
|
-- |
|
$9.22M |
|
$-9.22M |
|
$0.74M |
|
$-8.48M |
|
|
Normalized Pre-Tax Income |
$-8.48M |
$-8.48M |
|
$-8.48M |
|
$-8.48M |
|
$-8.48M |
|
$-9.22M |
|
$-8.84M |
|
33.82M |
|
33.82M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$11.96M |
|
-- |
|
$0.18M |
|
$12.15M |
|
$0.49M |
|
-- |
|
-- |
|
$0.49M |
|
$11.66M |
|
$11.66M |
|
$11.66M |
|
41.09M |
|
| Cash Flow Statement Financials | |
$-6.35M |
|
-- |
|
$14.88M |
|
$3.09M |
|
$11.63M |
|
$8.53M |
|
$1.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
24.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.35M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-72.78% |
|
-72.78% |
|
-69.86% |
|
-72.78% |
|
$0.28 |
|
$-0.19 |
|
$-0.19 |
|